Search research articles
Contact Us
Filters
Showing results (21-30 of 121) with videos related to
Page
of 13
Sort By:
Investigational New Drugs
|
January 17, 2022
Real-world data of off-label drug use in patients with actionable genomic alterations on next-generation sequencing
Gabriel Roman Souza, Ahmed Abdalla, Sukeshi Arora, et al.
Expert Opinion on Investigational Drugs
|
July 27, 2017
Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors
Hani M Babiker, Ali McBride, Laurence S Cooke, et al.
The Journal of Biological Chemistry
|
August 10, 2005
A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2)
Xiaohong Zhang, Nikhil V Shirahatti, Daruka Mahadevan, et al.
Expert Opinion on Investigational Drugs
|
April 4, 2018
Ublituximab for the treatment of CD20 positive B-cell malignancies
Hani M Babiker, Ashley E Glode, Laurence S Cooke, et al.
Molecular Cancer Therapeutics
|
February 5, 2024
Polyploidy in Cancer: Causal Mechanisms, Cancer-Specific Consequences, and Emerging Treatments
Patrick J Conway, Jonathan Dao, Dmytro Kovalskyy, et al.
Archives of Biochemistry and Biophysics
|
August 18, 2004
Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity
Emmanuelle J Meuillet, Daruka Mahadevan, Margareta Berggren, et al.
Leukemia Research
|
July 27, 2014
Genetic and cytokine changes associated with symptomatic stages of CLL
Amit Agarwal, Lawrence Cooke, Christopher Riley, et al.
Cancers
|
November 13, 2021
Expression Levels of RAD51 Inversely Correlate with Survival of Glioblastoma Patients
Christopher Morrison, Eric Weterings, Daruka Mahadevan, et al.
Oncotarget
|
October 28, 2015
Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer
Wenqing Qi, Carla Morales, Laurence S Cooke, et al.
Radiation Oncology (London, England)
|
December 24, 2009
The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
James W Welsh, Daruka Mahadevan, Ron Ellsworth, et al.
Page
of 13
Search research articles
Search
Showing results (21-30 of 121) with videos related to
Sort By:
Page
of 13
Investigational New Drugs
|
January 17, 2022
Real-world data of off-label drug use in patients with actionable genomic alterations on next-generation sequencing
Gabriel Roman Souza, Ahmed Abdalla, Sukeshi Arora, et al.
Expert Opinion on Investigational Drugs
|
July 27, 2017
Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors
Hani M Babiker, Ali McBride, Laurence S Cooke, et al.
The Journal of Biological Chemistry
|
August 10, 2005
A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2)
Xiaohong Zhang, Nikhil V Shirahatti, Daruka Mahadevan, et al.
Expert Opinion on Investigational Drugs
|
April 4, 2018
Ublituximab for the treatment of CD20 positive B-cell malignancies
Hani M Babiker, Ashley E Glode, Laurence S Cooke, et al.
Molecular Cancer Therapeutics
|
February 5, 2024
Polyploidy in Cancer: Causal Mechanisms, Cancer-Specific Consequences, and Emerging Treatments
Patrick J Conway, Jonathan Dao, Dmytro Kovalskyy, et al.
Archives of Biochemistry and Biophysics
|
August 18, 2004
Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity
Emmanuelle J Meuillet, Daruka Mahadevan, Margareta Berggren, et al.
Leukemia Research
|
July 27, 2014
Genetic and cytokine changes associated with symptomatic stages of CLL
Amit Agarwal, Lawrence Cooke, Christopher Riley, et al.
Cancers
|
November 13, 2021
Expression Levels of RAD51 Inversely Correlate with Survival of Glioblastoma Patients
Christopher Morrison, Eric Weterings, Daruka Mahadevan, et al.
Oncotarget
|
October 28, 2015
Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer
Wenqing Qi, Carla Morales, Laurence S Cooke, et al.
Radiation Oncology (London, England)
|
December 24, 2009
The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
James W Welsh, Daruka Mahadevan, Ron Ellsworth, et al.
Page
of 13